Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
25
TLPPF Quote, Financials, Valuation and Earnings
Last price:
$8.06
Seasonality move
:
30.39%
Day range:
$7.57 - $8.06
52-week range:
$7.50 - $24.85
Dividend yield:
0%
P/E ratio:
260.00x
P/S ratio:
4.18x
P/B ratio:
22.83x
Volume:
2.8K
Avg. volume:
2.7K
1-year change:
-48%
Market cap:
$2.7B
Revenue:
$516.6M
EPS (TTM):
$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLPPF
Telix Pharmaceuticals Ltd.
|
$222.5M | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $19.01 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLPPF
Telix Pharmaceuticals Ltd.
|
$8.06 | -- | $2.7B | 260.00x | $0.00 | 0% | 4.18x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.17 | $12.00 | $57.5M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$3.13 | $9.50 | $455.6M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$7.57 | $19.01 | $12.6M | -- | $0.00 | 0% | 342.04x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLPPF
Telix Pharmaceuticals Ltd.
|
50.11% | 0.055 | -- | 2.63x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLPPF
Telix Pharmaceuticals Ltd.
|
-- | -- | 6.6% | 13.56% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Telix Pharmaceuticals Ltd. vs. Competitors
-
Which has Higher Returns TLPPF or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Telix Pharmaceuticals Ltd.'s net margin of --. Telix Pharmaceuticals Ltd.'s return on equity of 13.56% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLPPFTelix Pharmaceuticals Ltd.-- -- $708.3M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About TLPPF or ATHE?
Telix Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 278.55%. Given that Alterity Therapeutics Ltd. has higher upside potential than Telix Pharmaceuticals Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Telix Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLPPFTelix Pharmaceuticals Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is TLPPF or ATHE More Risky?
Telix Pharmaceuticals Ltd. has a beta of 2.101, which suggesting that the stock is 110.076% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.023, suggesting its less volatile than the S&P 500 by 97.656%.
-
Which is a Better Dividend Stock TLPPF or ATHE?
Telix Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telix Pharmaceuticals Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLPPF or ATHE?
Telix Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Telix Pharmaceuticals Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Telix Pharmaceuticals Ltd.'s price-to-earnings ratio is 260.00x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telix Pharmaceuticals Ltd. is 4.18x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLPPFTelix Pharmaceuticals Ltd.4.18x 260.00x -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns TLPPF or IMMP?
Immutep Ltd. has a net margin of -- compared to Telix Pharmaceuticals Ltd.'s net margin of --. Telix Pharmaceuticals Ltd.'s return on equity of 13.56% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLPPFTelix Pharmaceuticals Ltd.-- -- $708.3M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About TLPPF or IMMP?
Telix Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 203.51%. Given that Immutep Ltd. has higher upside potential than Telix Pharmaceuticals Ltd., analysts believe Immutep Ltd. is more attractive than Telix Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLPPFTelix Pharmaceuticals Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is TLPPF or IMMP More Risky?
Telix Pharmaceuticals Ltd. has a beta of 2.101, which suggesting that the stock is 110.076% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.925, suggesting its more volatile than the S&P 500 by 92.469%.
-
Which is a Better Dividend Stock TLPPF or IMMP?
Telix Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telix Pharmaceuticals Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLPPF or IMMP?
Telix Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Telix Pharmaceuticals Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Telix Pharmaceuticals Ltd.'s price-to-earnings ratio is 260.00x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telix Pharmaceuticals Ltd. is 4.18x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLPPFTelix Pharmaceuticals Ltd.4.18x 260.00x -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns TLPPF or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Telix Pharmaceuticals Ltd.'s net margin of --. Telix Pharmaceuticals Ltd.'s return on equity of 13.56% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital TLPPFTelix Pharmaceuticals Ltd.-- -- $708.3M KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About TLPPF or KZIA?
Telix Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $19.01 which suggests that it could grow by 151.57%. Given that Kazia Therapeutics Ltd. has higher upside potential than Telix Pharmaceuticals Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Telix Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLPPFTelix Pharmaceuticals Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is TLPPF or KZIA More Risky?
Telix Pharmaceuticals Ltd. has a beta of 2.101, which suggesting that the stock is 110.076% more volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock TLPPF or KZIA?
Telix Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telix Pharmaceuticals Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLPPF or KZIA?
Telix Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Telix Pharmaceuticals Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Telix Pharmaceuticals Ltd.'s price-to-earnings ratio is 260.00x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telix Pharmaceuticals Ltd. is 4.18x versus 342.04x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLPPFTelix Pharmaceuticals Ltd.4.18x 260.00x -- -- KZIAKazia Therapeutics Ltd.342.04x -- -- --
-
Which has Higher Returns TLPPF or PPCB?
has a net margin of -- compared to Telix Pharmaceuticals Ltd.'s net margin of --. Telix Pharmaceuticals Ltd.'s return on equity of 13.56% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLPPFTelix Pharmaceuticals Ltd.-- -- $708.3M PPCB-- -$0.00 -- -
What do Analysts Say About TLPPF or PPCB?
Telix Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Telix Pharmaceuticals Ltd. has higher upside potential than , analysts believe Telix Pharmaceuticals Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings TLPPFTelix Pharmaceuticals Ltd.0 0 0 PPCB0 0 0 -
Is TLPPF or PPCB More Risky?
Telix Pharmaceuticals Ltd. has a beta of 2.101, which suggesting that the stock is 110.076% more volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock TLPPF or PPCB?
Telix Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telix Pharmaceuticals Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLPPF or PPCB?
Telix Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Telix Pharmaceuticals Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Telix Pharmaceuticals Ltd.'s price-to-earnings ratio is 260.00x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telix Pharmaceuticals Ltd. is 4.18x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLPPFTelix Pharmaceuticals Ltd.4.18x 260.00x -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
